2013
DOI: 10.1016/j.biomaterials.2013.03.094
|View full text |Cite
|
Sign up to set email alerts
|

The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
63
2

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 103 publications
(70 citation statements)
references
References 47 publications
5
63
2
Order By: Relevance
“…Effect of the Growth Rate of the Cells on the Sensitivity to DOX To evaluate the effect of the cellular growth rate on the cytotoxic effect of DOX, we calculated the growth rate of the cancer cells following the protocol as we reported before (20). Based on the results presented in Fig.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…Effect of the Growth Rate of the Cells on the Sensitivity to DOX To evaluate the effect of the cellular growth rate on the cytotoxic effect of DOX, we calculated the growth rate of the cancer cells following the protocol as we reported before (20). Based on the results presented in Fig.…”
Section: Resultsmentioning
confidence: 99%
“…To inhibit the expression and function of P-gp, the cells were treated with Verapamil. [16][17][18] In the case of OSRC-2 cells, a class of RCC, which are intrinsically resistant to chemotherapy, [20][21][22][23][24] the EC 50 to DOX was calculated to be 71.15 µg/mL. Even though, the inhibition of P-gp by verapamil induces a 2-fold increment in the amount of internalized DOX (Figs.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Taken together, RGD-MEND appears to be tumor-specific, and therefore a safe carrier to TECs. We recently reported that a large RGD modified carrier (>300 nm) can efficiently target the tumor vasculature due to multivalent association between the carrier and its receptor [47]. Based on these new findings, an siRNA-encapsulating RGD-MEND would be an alternative strategy for anti-angiogenic therapy instead of a small molecule inhibitor and an antibody.…”
Section: Sirna Delivery To Tumors and The Tumor Vasculature Using A Pmentioning
confidence: 98%